The aldosterone-renin ratio (ARR) has gained popularity as a screening test for primary hyperaldosteronism, a probably underdiagnosed cause of hypertension. However, studies have yielded varying ...

Spironolactone is only FDA approved for treatment of heart failure with reduced ejection fraction, adjunctive blood pressure lowering in hypertension, edema, and primary hyperaldosteronism.

Center for Adrenal Disorders, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA (C.-H.T., J.M ...

The finding that angiotensin II and aldosterone are proinflammatory ... lowering observed with such treatment in patients with primary hyperaldosteronism. The role of the RAAS in the worldwide ...

The investigational aldosterone synthase inhibitor lorundrostat effectively lowered 24-hour BP for adults with well-treated, ...

Among patients with uncontrolled hypertension, the investigational drug lorundrostat brought a significant reduction in blood ...

Among patients with uncontrolled hypertension, the investigational drug lorundrostat brought a significant reduction in blood pressure at 12 weeks compared with placebo, according to a study presented ...

Many existing blood pressure-lowering drugs work by blocking aldosterone from binding to ... meeting the trial's primary endpoint. The results showed consistent patterns across secondary endpoints ...

Lorundrostat is an orally-administered highly selective aldosterone synthase inhibitor ... or placebo. The primary endpoint was the change from baseline in systolic blood pressure (SBP) after ...